Bio-cosmetics in China in 2025 data
- Giant Biogene, a leader in recombinant collagen, reported 2025 revenue of RMB 5.519 billion, down 0.37%, and net profit of RMB 1.915 billion, down 7.15%, its first profit decline since listing, says Deep News on Tiger Brokers.
- Its Curlig brand grew 9.2% to RMB 918 million, and offline direct sales rose 32.2% to RMB 225 million.
- In 2023, recombinant collagen functional skincare was a RMB 11.54 billion market, medical dressings RMB 11 billion and medical aesthetic injectables RMB 4.3 billion.
- Approved injectable collagen products in China rose from 3 to 6, with Giant Biogene receiving approvals in October 2025 and January 2026.
- Domestic cosmetics brands held 57.4% of the Chinese market in 2025, as covered in our work on the make-up market in China.
Bio-cosmetics moved from “natural plant extracts” to “bio-engineered ingredients”, and the market now looks more like a technology sector than a herbal one.

What bio-cosmetics meant at the start
Our first research defined bio-cosmetics as products that use organic and natural, ingredients, extracted from plants, and that are friendly to the environment.
China was already the fastest-growing cosmetics market, for several reasons:
- Registration was fast. It took only 40 to 60 days for ordinary cosmetics to get production registration or an import permit.
- The market focused on women. Almost half of Chinese women lived in cities, and more rural women were moving to cities for better jobs.
- According to the National Bureau of Statistics, about 167 million urban women aged 20 to 50 lived in China in 2012. This group had the strongest desire to try organic and natural products, even rarely heard ones with good quality.
- Some overseas brands without stores in China still received mail orders thanks to mouth-to-mouth marketing.
The first wave of local herbal brands
Two names showed the strength of the segment. Xiang Yi Ben Cao reached revenue above US$133 million in 2013, with A profit margin of 18.06%. Herborist created over US$80 million of revenue in 2012, with quarterly sales growth of 16.66%.
Their success relied on wide online and offline distribution. Herborist had more than 1,000 stores, including independent stores and counters in cosmetics distributors,. and opened online shops on almost every popular platform. Both brands targeted ordinary people, with prices from about US$8 to US$23.
Science was also part of the story. In 2013, Jala cooperated with the Shenzhou 10 spacecraft mission for research, and used tools such as a 3D skin cell model.
The second wave: recombinant collagen and medical aesthetics
- Functional skincare. Serums and creams with recombinant collagen, hyaluronic acid or other bio-engineered ingredients, sold as science-led.
- Medical dressings. Sheets and patches used after procedures, regulated as medical devices.
- Injectables. The highest value segment, where each approval creates a strong barrier. Jinbo Biological, the former sole player, saw first-half 2025 medical device revenue grow 33.41% to RMB 708 million with a 95.04% gross margin.
Giant Biogene shows the opportunity and the stress. Its market value passed RMB 80 billion within three years of the November 2022 Hong Kong listing, yet the 2025 results show a slowdown. Revenue growth had been around 50% a year from 2022 to 2024, and in the second half of 2025 revenue fell 19.76% from the same period of 2024, as promotion costs and competition increased.
What this means for brands
- Claims need proof. Regulators and consumers now question words such as “collagen” and “repair”.
- Approvals give a long head start. Each injectable approval is a license that rivals need years to match.
- Price stays under pressure. Many new entrants launch similar ingredient stories at lower prices.
- Offline matters again. Giant Biogene’s direct offline sales grew 32.2%, since medical products need professionals and trust.
How to read the shift from herbal to biotech
The first wave sold a feeling: gentle, traditional, close to nature. The second wave sells a mechanism: a named molecule, a lab test and a regulatory file. Consumers still like natural images, but they now ask what an ingredient does, and whether the claim is supported by data.
For marketing teams, this changes the content plan. Ingredient pages, dermatologist interviews and open lab visits replace pure lifestyle imagery. For product teams, it means that formulas must be stable, safe and traceable, and that suppliers must be audited.
It also changes who competes. A herbal brand competed with other brands. A biotech skincare company also competes with clinics, pharmaceutical groups and device makers, because some products sit on the line between a cosmetic and a medical treatment. Brands that understand where that line is drawn can enter the high-value segments, while others may face fines or product removal.
Daxue Take
We would consider these options, with their limits:
- If the company is a foreign ingredient supplier, partner with a local brand that already owns the consumer, and protect patents in China from the start.
- If the company is a skincare brand, pick one proven ingredient and publish test data. Broad claims create regulatory and reputation risks.
- If the company targets medical aesthetics, plan for years of approval work and for a distribution model based on clinics.
- If the company is an investor, compare revenue growth with cost of promotion, as the 2025 results show a big difference between the two.
The limit is regulation. Rules on classification between cosmetics and medical devices are tight and can change, so legal advice should come before the product plan.
What to watch next
- New injectable approvals and their effect on prices.
- Whether Giant Biogene returns to growth in 2026.
- Rules on collagen claims in cosmetics.
- Our related reading on cosmetic brands in China and the herbal medicine market.
FAQ
What are bio-cosmetics?
Cosmetics based on natural or bio-engineered ingredients, such as plant extracts or recombinant collagen.
How big is the recombinant collagen market in China?
In 2023 functional skincare was RMB 11.54 billion, dressings RMB 11 billion and injectables RMB 4.3 billion.
Is Giant Biogene still growing?
Its 2025 revenue fell 0.37% and profit fell 7.15%.
How long did registration take in the past?
About 40 to 60 days for ordinary cosmetics, according to our early research.
Who were the early herbal brands?
Xiang Yi Ben Cao and Herborist.
About Daxue Consulting
Daxue Consulting is a market research and strategy consulting firm focused on China, founded in Beijing in 2012, with offices in Shanghai, Beijing and Hong Kong. We have delivered more than 800 projects for international brands. To discuss bio-cosmetics and skincare in China, see our market research services or contact our team.

